OTC Token Sale
A negotiated, off-exchange sale of tokens that already exist, usually out of a project treasury. It mints no supply, and because the tokens sold are usually locked or reserved it moves no circulating figure either; what changes is who owns the tokens and what they intend to do with them. WLFI's treasury allocation fell about 6.91B tokens between September 2025 and May 2026 while its insider and partner pool rose 5.88B, a shift the project attributed to private treasury sales.
TradFi parallel: A secondary block trade in private company shares. No new stock is issued and the total is unchanged, but a patient holder is replaced by one with a different cost basis, a different horizon, and no obligation to say so.
Key Takeaways
- 01An OTC sale is negotiated off-exchange rather than on an order book, mints nothing, and leaves circulating supply unchanged whenever the tokens sold were locked or reserved: only ownership moves
- 02It converts protocol-controlled reserves into investor-owned supply, replacing project deployment decisions with investor exit decisions as the driver of future release
- 03Supply models that treat all treasury tokens as non-circulating can understate future float risk when a meaningful share has been privately placed
- 04WLFI's sales surfaced only as a 5.88B discrepancy between a September 2025 disclosure and an April 2026 governance proposal, with the treasury allocation down about 6.91B over the same period
- 05Buyers, prices, lockup terms and transfer restrictions are typically undisclosed, so ownership concentration and the timing of future liquidity cannot be assessed from public data
- 06Where OTC placement is heavy, reported float can badly overstate the tradeable market: insiders were alleged to control upwards of 95% of LAB's effective float
How It Works
An OTC token sale transfers tokens that already exist, negotiated bilaterally rather than executed on an order book. Because nothing is minted and the tokens sold are typically locked or held in reserve, none of the headline supply metrics move: max supply, total supply and circulating supply all stay where they were. That is a property of the tokens being locked rather than of the sale, because most methodologies exclude project-controlled wallets, so selling treasury tokens that are already unlocked to a third party can raise reported circulating supply. In the locked case ownership is the only thing that changes, and it usually changes invisibly. World Liberty Financial's WLFI is the clearest documented case in Tokenomist's coverage. Its September 2025 launch disclosure placed 39.36B WLFI across Team, Advisors and Strategic Partners. Its April 2026 governance proposal listed 45.24B for founders, team members, advisers and partners, and did not reconcile the 5.88B increase or reference the earlier disclosure. After Tokenomist identified the gap, World Liberty Financial told Bloomberg that private white glove treasury sales to accredited investors had occurred, without specifying the number of tokens sold, the buyers, the prices, or the lockup terms. Over the same period the treasury allocation fell from 19,955,030,000 to 13,048,677,530, about 6.91B tokens. Maximum supply stayed at 100B throughout.
Selling treasury tokens is not dilution in the literal sense, since the tokens were always part of total supply. What it does is convert protocol-controlled reserves into investor-owned supply, and that swaps out the behavioural assumption attached to them. A treasury balance releases according to the project's deployment decisions, which are at least nominally tied to protocol needs. A private investor's balance releases according to that investor's incentives and exit plan once restrictions expire. Tokenomist's conclusion is stated plainly: supply models that treat all treasury tokens as non-circulating may understate future float risk if many have been privately placed, though the timing and likelihood of sales remain unknown. The same logic makes an unexplained decline in a treasury allocation worth treating as a supply event, even when no unlock is scheduled and no on-chain release has occurred.
The difficulty is evidentiary. An OTC sale leaves no trace in price data, market capitalisation or circulating supply, which is where most supply analysis looks. WLFI's surfaced only as a difference between two documents seven months apart, and the 5.88B figure is Tokenomist's calculation from the allocation delta, not a quantity the project stated. Differing category labels and the absence of wallet-level data meant the comparison could not independently confirm how tokens moved between allocations, and a separate Reuters analysis of an approximately 3B decline in issuer-retained WLFI between September and October 2025 could not be reconciled with the gap, so it was excluded from the analysis. Documented cases are rare because the documentation is rare, not because the practice is: Tokenomist describes OTC and private treasury sales as common in the industry.
Where private placement runs deep enough, the published float stops describing the tradeable market at all. On-chain investigator ZachXBT has alleged since May 2026 that insiders control upwards of 95% of LAB's effective float through OTC deals, private allocations and team-linked wallets, as part of an investigation citing opaque private loans, unilateral vesting changes and an unknown float behind the token's run to a $6B FDV. The LAB team attributed the subsequent decline, roughly 85% to 90% from the highs, to large market participants and unaffiliated trading firms and said its roadmap was unchanged. Those remain reported allegations and responses rather than settled facts, which is the state most OTC questions stay in. The practical response is to stop modelling supply as one pool: token sale proceeds, treasury-controlled allocations, privately placed tokens and governance-locked tokens each deserve separate categories with distinct behavioural assumptions, because FDV accounts for full supply without distinguishing between them.
Real World Examples
World Liberty Financial (WLFI): a 5.88B gap between two disclosures
View →The September 2025 launch record placed 39.36B WLFI across Team, Advisors and Strategic Partners; the April 2026 governance proposal listed 45.24B for founders, team, advisers and partners without reconciling the increase. WLFI later told Bloomberg that private white glove treasury sales to accredited investors had occurred, but did not state how many tokens were sold.
WLFI treasury: 6.91B tokens out, 100B max supply unchanged
View →Tokenomist's May 12, 2026 snapshot showed the treasury at 13,048,677,530 WLFI, down about 6.91B from 19,955,030,000 in September 2025, with no change to the 100B ceiling. The April 2026 proposal then offered holders a defined path for the reclassified supply: a 2-year cliff followed by 3 years of linear vesting on up to 40.71B tokens, with up to 4.52B burned by opt-in holders.
LAB: OTC deals alleged behind an unknown float
View →ZachXBT alleged from May 2026 that insiders controlled upwards of 95% of LAB's effective float through OTC deals, private allocations and team-linked wallets, in an investigation citing opaque private loans, unilateral vesting changes and an unknown float behind a run to $6B FDV. LAB fell roughly 85% to 90% from its highs in early July 2026; the team attributed the move to unaffiliated trading firms. These are reported allegations, not settled facts.
Frequently Asked Questions
Does an OTC sale increase circulating supply?
Usually not, and that is exactly why it is easy to miss. The tokens already existed and are usually still locked or reserved after the sale, so circulating supply, total supply and max supply are all unchanged. What moves is the identity of the holder and, with it, the assumption that governs when those tokens reach the market. The exception is a sale of tokens that are already unlocked: most methodologies exclude project-controlled wallets, so moving unlocked treasury tokens to a third party can raise the reported figure even though nothing was minted.
How would I detect one?
Usually by comparing disclosures rather than by watching the chain. WLFI's private sales surfaced as a 5.88B difference between its September 2025 allocation record and its April 2026 governance proposal, alongside a roughly 6.91B decline in the treasury allocation. That means tracking allocation tables across time, noting reclassifications between categories, and treating an unexplained treasury decline as a signal. On-chain proof requires wallet-level attribution, which is often unavailable.
Is an OTC sale a bad sign?
Not by itself. Treasuries sell tokens to fund operations, and doing so privately avoids the market impact of selling into an order book. The issue is informational: buyers, prices, lockup terms and transfer restrictions are typically undisclosed, so the market cannot assess ownership concentration, holder incentives, or the likelihood and timing of future liquidity. The risk is that a supply model keeps counting those tokens as passive treasury reserves long after they stopped being that.
How should privately placed tokens be modelled?
As their own supply category. Tokenomist's guidance is to separate token sale proceeds, treasury-controlled allocations, privately placed tokens and governance-locked tokens, each with distinct behavioural assumptions, because FDV covers full supply without distinguishing between protocol reserves, private investor holdings and team allocations. Privately placed tokens should carry investor-style exit assumptions, not treasury-style deployment assumptions, even while they remain locked.
Related Terms
Track on Tokenomist
Supply-side analysis for educational purposes. Not financial advice. Verify assumption and precision labels on the relevant token page.